Vinva Investment Management Ltd Lowers Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Vinva Investment Management Ltd trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 59.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,264 shares of the medical equipment provider’s stock after selling 19,145 shares during the quarter. Vinva Investment Management Ltd’s holdings in Hologic were worth $959,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. First Horizon Advisors Inc. raised its position in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares in the last quarter. Brooklyn Investment Group raised its position in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC raised its position in Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 169 shares in the last quarter. Finally, Loomis Sayles & Co. L P raised its position in Hologic by 29.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 183 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on HOLX. Royal Bank of Canada reduced their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Jefferies Financial Group initiated coverage on Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price on the stock. Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Finally, Evercore ISI cut their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Trading Down 0.7 %

NASDAQ:HOLX opened at $61.01 on Friday. The stock’s 50 day moving average price is $66.26 and its 200 day moving average price is $74.19. The company has a market capitalization of $13.69 billion, a PE ratio of 19.25, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.